|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500102340 |
|
最近更新日期: Date of Last Refreshed on: |
2025-05-13 15:25:45 |
|
注册时间: Date of Registration: |
2025-05-13 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
心血管疾病家庭医院整合照护模式的构建及效果评价 |
|
Public title: |
Construction and effect evaluation of the integrated hospital-at-home care model for cardiovascular diseases |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于系统动力学的心血管疾病家庭医院整合照护模式构建及干预研究 |
|
Scientific title: |
Development and implementation of hospital-at-home integrated care model for cardiovascular disease based on system dynamics |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王喜益 |
研究负责人: |
许莉 |
|
Applicant: |
Xiyi Wang |
Study leader: |
Li Xu |
|
申请注册联系人电话: Applicant telephone: |
+86 191 0175 1926 |
研究负责人电话: Study leader's telephone: |
+86 135 0183 0955 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wangxiyi4869@shsmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
xuli@renji.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市黄浦区重庆南路227号东1舍213办公室 |
研究负责人通讯地址: |
上海市东方路1630号 |
|
Applicant address: |
Room 213, Building No.1, 227 Chongqing Road South, Huangpu District, Shanghai |
Study leader's address: |
1630 Dongfang Road, Shanghai |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
上海交通大学医学院 |
||
|
Applicant's institution: |
Shanghai Jiao Tong University School of Medicine |
||
|
研究负责人所在单位: |
上海交通大学医学院附属仁济医院 |
||
|
Affiliation of the Leader: |
Shanghai Jiaotong University School of Medicine, Renji Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY2024-205-C |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
上海交通大学医学院附属仁济医院伦理委员会 |
||
|
Name of the ethic committee: |
Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-15 00:00:00 |
||
|
伦理委员会联系人: |
曹晖 |
||
|
Contact Name of the ethic committee: |
Cao Hui |
||
|
伦理委员会联系地址: |
上海市东方路1630号 |
||
|
Contact Address of the ethic committee: |
1630 Dongfang Road, Shanghai |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 21 6838 3364 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
上海交通大学医学院附属仁济医院 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Shanghai Jiaotong University School of Medicine Renji Hospital |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
上海市东方路1630号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
1630 Dongfang Road, Shanghai |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金委员会 |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
National Natural Science Foundation of China (NSFC) |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
Cardiovascular disease |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
开展随机对照试验,验证心血管疾病家庭医院整合照护方案的可行性和有效性。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
Conduct randomized controlled trials to verify the feasibility and effectiveness of integrated care programs for cardiovascular diseases in home healthcare. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
① 由专科医生诊断为心血管疾病(包括冠脉疾病、 瓣膜疾病、 心律失常); ② 患者病情稳定,二级护理; ③ 根据出院/转科标准,由心脏重症监护病房(CCU)转出,至普通病房,或患者意愿直接出院回家; ④ 年龄≥18 岁; ⑤ 愿意持续来院门诊就诊; ⑥ 与主要照护者同住; ⑦ 知情同意并签署同意书。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
1.Diagnosed with a cardiovascular condition—such as coronary artery disease, valvular heart disease, or arrhythmia—by a qualified specialist. 2.The patient's clinical condition is stable and currently managed at the secondary care level. 3.The patient has either: been transferred from the Cardiac Intensive Care Unit (CCU) to a general ward in accordance with established discharge/transfer criteria, or been discharged directly to their home. 4.Aged 18 years or older. 5.Willing to attend follow-up visits at the hospital outpatient clinic. 6.Resides with a primary caregiver. 7.Has provided informed consent and signed the consent form. |
||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
①患有严重精神疾病或智力受损无法自主表达意愿;②已参与其他健康干预项目。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1.Diagnosed with a severe mental illness or intellectual disability that impairs the ability to express their own wishes independently. 2.Currently participating in another health intervention program. |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-05-19 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
符合纳入标准的研究对象将按照1:1的比例随机分配至干预组(家庭医院模式)或对照组(常规住院治疗)。随机分组将采用计算机生成的随机数字序列,以确保分组过程的隐蔽性,最大程度减少选择偏倚。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Eligible participants will be randomly assigned in a 1:1 ratio to either the intervention group (Hospital-at-Home model) or the control group (standard in-hospital care). Randomization will be conducted using a computer-generated random number sequence to ensure allocation concealment and minimize selection bias. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
由于干预形式差异明显,患者和干预执行人员无法实现盲法,因此仅对结果评估人员(包括负责数据分析的统计学人员)实施盲法,以降低观察者偏倚和评估偏倚。所有结局指标的评估将依据预设标准和统一流程进行,确保数据客观性和科学性。 |
|
Blinding: |
A single-blind design will be employed. Due to the nature of the intervention, blinding of participants and intervention providers is not feasible. However, outcome assessors, including those responsible for data analysis, will remain blinded to group allocation in order to reduce observer and assessment bias. All outcome measures will be evaluated according to standardized protocols to ensure objectivity and scientific rigor. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
NA |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表(Excel) 医院信息系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form Hospital electronic system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |